While Akero Therapeutics Inc has overperformed by 0.97%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AKRO fell by -33.66%, with highs and lows ranging from $58.38 to $11.25, whereas the simple moving average fell by -5.82% in the last 200 days.
On September 19, 2023, Cantor Fitzgerald started tracking Akero Therapeutics Inc (NASDAQ: AKRO) recommending Overweight. A report published by UBS on August 28, 2023, Initiated its previous ‘Buy’ rating for AKRO. Morgan Stanley also Upgraded AKRO shares as ‘Overweight’, setting a target price of $65 on the company’s shares in a report dated January 27, 2023. Evercore ISI September 14, 2022d the rating to Outperform on September 14, 2022, and set its price target from $10 to $50. Morgan Stanley October 19, 2021d its ‘Overweight’ rating to ‘Equal-Weight’ for AKRO, as published in its report on October 19, 2021. BofA Securities’s report from September 10, 2021 suggests a price prediction of $40 for AKRO shares, giving the stock a ‘Buy’ rating. Guggenheim also rated the stock as ‘Buy’.
Analysis of Akero Therapeutics Inc (AKRO)
To gain a thorough understanding of Akero Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -35.22% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 29.27, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and AKRO is recording an average volume of 1.35M. On a monthly basis, the volatility of the stock is set at 10.02%, whereas on a weekly basis, it is put at 12.84%, with a gain of 12.12% over the past seven days. Furthermore, long-term investors anticipate a median target price of $51.25, showing growth from the present price of $31.18, which can serve as yet another indication of whether AKRO is worth investing in or should be passed over.
How Do You Analyze Akero Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.00%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.47% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AKRO shares are owned by institutional investors to the tune of 101.47% at present.
